Large holder notice
Open the filing on sec.gov
Edesa Biotech, Inc. (EDSA)
Nasdaq: EDSA · Pharmaceutical Preparations · filing with the SEC since 2012
The companyfiscal 2021, as filed
Revenue$0.00-100.0%
Net income-$13.3M-109.7%
Earnings per sharen/a
Operating cash flow-$13.7M-174.0%
Cash$7.8M+8.7%
Debtn/a
Shareholders’ equity$13.1M+96.9%
Shares, dilutedn/a
Return on equity-57.7%
The recordfrom its filings
Filings in 202671
Newest filingNov 12 · SCHEDULE 13G
Annual reportDec 12, 2025
Quarterly reportAug 13, 2026
Next report due10-K by Dec 29
Insider sales, 12 months$0.00
Insider buys, 12 months$200,000
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$14.1MCash from operations -$8.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.